Gilead Sciences (NASDAQ:GILD) PT Lowered to $74.00

Gilead Sciences (NASDAQ:GILD) had its price target lowered by Royal Bank of Canada from $76.00 to $74.00 in a report released on Friday, Benzinga reports. Royal Bank of Canada currently has a sector perform rating on the biopharmaceutical company’s stock.

GILD has been the topic of several other reports. Cantor Fitzgerald dropped their target price on Gilead Sciences from $80.00 to $78.00 and set a neutral rating on the stock in a research report on Wednesday, February 7th. UBS Group dropped their target price on Gilead Sciences from $81.00 to $75.00 and set a neutral rating on the stock in a research report on Wednesday, April 17th. Mizuho dropped their target price on Gilead Sciences from $101.00 to $90.00 and set a buy rating on the stock in a research report on Thursday, February 22nd. Wells Fargo & Company dropped their target price on Gilead Sciences from $84.00 to $77.00 and set an equal weight rating on the stock in a research report on Monday, March 4th. Finally, Oppenheimer reissued an outperform rating and issued a $105.00 target price on shares of Gilead Sciences in a research report on Friday, April 19th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Gilead Sciences has an average rating of Hold and an average price target of $83.87.

Gilead Sciences Trading Up 0.2 %

Gilead Sciences stock opened at $65.42 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. Gilead Sciences has a one year low of $64.63 and a one year high of $87.86. The stock has a market capitalization of $81.45 billion, a PE ratio of 181.72, a price-to-earnings-growth ratio of 1.17 and a beta of 0.19. The business’s fifty day moving average is $71.28 and its 200 day moving average is $76.25.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a return on equity of 23.08% and a net margin of 1.76%. The company had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. During the same period last year, the firm posted $1.37 earnings per share. Gilead Sciences’s revenue was up 5.3% compared to the same quarter last year. On average, sell-side analysts predict that Gilead Sciences will post 4.2 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 4.71%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total transaction of $146,360.00. Following the sale, the insider now owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors have recently added to or reduced their stakes in the company. Nilsine Partners LLC grew its holdings in Gilead Sciences by 1.1% during the 3rd quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock valued at $891,000 after buying an additional 127 shares in the last quarter. Etesian Wealth Advisors Inc. grew its holdings in Gilead Sciences by 0.7% during the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after buying an additional 128 shares in the last quarter. Financial Counselors Inc. boosted its holdings in shares of Gilead Sciences by 1.5% in the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 128 shares during the period. Revolve Wealth Partners LLC boosted its holdings in shares of Gilead Sciences by 3.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 130 shares during the period. Finally, Institutional & Family Asset Management LLC boosted its holdings in shares of Gilead Sciences by 10.3% in the 3rd quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 140 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.